TEPEZZA

all catalysts(0)

nothing on the calendar yet

News(10)

• Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren's study
  Amgen is awaiting another Phase 3 readout for the investigational Sjögren's disease therapy, set for later this year. William Blair anticipates that at least two trials will be needed to support an…
  biospace · 6d ago
• Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
  An investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive sign for the Horizon Therapeutics-acquired pipeline that has so far str…
  fiercebiotech · 7d ago
• Sling banks $123M for an experimental thyroid eye disease pill
  A confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.
  biopharma_dive · 13d ago
• Sling catches $123M series C for thyroid eye disease pill
  Sling Therapeutics is advancing the first late-stage oral drug for thyroid eye disease that, if approved, could compete against Amgen and Viridian Therapeutics.
  biospace · 13d ago
• Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial
  Sling Therapeutics has closed a $123 million series C round to advance its oral therapy for thyroid eye disease through a phase 3 trial and hopefully on to commercialization.
  fiercebiotech · 14d ago
• Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
  Eli Lilly has struck a deal to acquire Merida Biosciences for up to $2.875 billion, establishing a beachhead in efforts to treat disease through the selective degradation of pathogenic autoantibodies.
  fiercebiotech · 29d ago
• Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
  Three years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture.
  fiercebiotech · 1mo ago
• Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A
  Amgen has discontinued Phase 1 obesity candidate AMG 513, leaving MariTide as its sole weight loss asset. Meanwhile, executives said the company’s late-stage pipeline is largely full and future bus…
  biospace · 1mo ago
• 7 companies hiring in New York now
  Looking for a biopharma job in New York? Check out the BioSpace list of seven companies hiring life sciences professionals like you.
  biospace · 2mo ago
• Viridian may have edge over Amgen in eye drug showdown, analysts argue
  The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.
  biopharma_dive · 3mo ago